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Aim.To examine the effect of berberine (BBR) on liver fibrosis and its possiblemechanisms through direct effects on hepatic stellate
cells (HSC).Methods.Theantifibrotic effect of BBRwas determined in a ratmodel of bile duct ligation- (BDL-) induced liver fibrosis.
Multiple cellular andmolecular approaches were introduced to examine the effects of BBR onHSC. Results. BBR potently inhibited
hepatic fibrosis induced by BDL in rats. It exhibited cytotoxicity to activated HSC at doses nontoxic to hepatocytes. High doses
of BBR induced apoptosis of activated HSC, which was mediated by loss of mitochondrial membrane potential and Bcl-2/Bax
imbalance. Low doses of BBR suppressed activation of HSC as evidenced by the inhibition of 𝛼-smooth muscle actin (𝛼-SMA)
expression and cell motility. BBR did not affect Smad2/3 phosphorylation but significantly activated 5󸀠 AMP-activated protein
kinase (AMPK) signalling, which was responsible for the transcriptional inhibition by BBR of profibrogenic factors 𝛼-SMA and
collagen in HSC. Conclusion. BBR is a promising agent for treating liver fibrosis through multiple mechanisms, at least partially by
directly targeting HSC and by inhibiting the AMPK pathway. Its value as an antifibrotic drug in patients with liver disease deserves
further investigation.
1. Introduction
Hepatic fibrosis is a common pathology in various progres-
sive chronic liver diseases [1]. Fibrogenesis in liver, which
often accompanies disease progression from hepatitis to can-
cerous transformation [2], is an abnormal process in which
the organ develops excessive accumulation of extracellular
matrix proteins in response to chronic injury [3]. Activation
of hepatic stellate cells (HSC) is critical in the fibrogenic
process of the liver and activated HSC are known as the main
sources of a pathogenic extracellular matrix proteins in liver
fibrosis [4, 5]. It is believed that effective treatment of hepatic
fibrosis will be both crucial for the prevention of chronic liver
failure and beneficial for the prevention of liver cancerous
diseases [6]; however, there is still no standard treatment for
liver fibrosis [7].
Berberine (BBR) is a natural alkaloid extracted from
Coptidis Rhizoma (Huang Lian in Chinese), an herbal drug
commonly used in traditional Chinese medicine for treating
patients with inflammatory diseases. The major pharmaco-
logical actions of BBR may include antimicrobial [8], anti-
inflammatory [9], antioxidative [10], and antitumoral activi-
ties [11]. Our previous studies have revealed the therapeutic
effects of Coptidis Rhizoma and BBR on hepatocellular
carcinoma, by inducing apoptotic and autophagic cell death
at high doses [12] and by repressing tumor cell motility
at lower doses [13]. These observations suggested that BBR
be of potential value for treating liver malignancies [14].
Furthermore, it was also found by our group that extract of
Coptidis Rhizoma exerted potent protective effect on acute
and chronic liver damage in an experimental animal model
of liver injury, significantly improving liver function and
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tissue structure [15, 16]. We further reported that, BBR, a
major active compound extracted from Coptidis Rhizoma
also protected animal from acute hepatic damage [17, 18].
BBR is able to reduce sustained and chronic liver injury
in various animal models of hepatic damage [19]. We have
proposed that BBR as an antifibrotic drug and itsmechanisms
of action are worth further investigation [20].
In this study, we aimed to investigate the in vitro and in
vivo antifibrotic effect of BBR and its potential mechanisms
with focus on HSC.The antifibrotic activity of BBR was eval-
uated in bile duct ligation-induced hepatic fibrosis model in
rats. The action of BBR on activated HSC was investigated at
both nontoxic and toxic levels. Understanding the action and
mechanism of BBR in inhibiting hepatic fibrosis may shed
light on the further development of antifibrotic treatment.
2. Materials and Methods
2.1. Chemicals and Reagents. BBR hydrochloride and Com-
pound C, an AMPK inhibitor, were purchased from Sigma-
Aldrich (USA).
2.2. Animals. Male SD rats of 220∼250 g body weight were
purchased from Guangdong Medical Laboratory Animal
Centre, Guangzhou, Guangdong Province, China. Animals
were housed at 25 ± 2∘C, with a 12 h light cycle, starting at
06:00, and were provided free access to standard laboratory
chow and water. All experiments were approved by the ethics
committee of theUniversity ofHongKong and compliedwith
international guidelines.
2.3. Animal Model. Bile duct ligation (BDL) was applied to
rats to induce extrahepatic cholestasis-related liver fibrosis.
Briefly, under anaesthesia with ether, rats were subjected to
ligation of the common bile duct with 3-0 silk and sectioned
between the ligatures. The abdominal midline was then
closed with catgut. Rats in a sham control group had their
bile duct exposed with neither ligation nor sectioning. All
rats were caged at 24∘C with 12 h : 12 h light-dark cycle and
were provided free access to food and water for 7 days
before the study. All operated rats except sham controls were
randomised into different groups.
2.4. Animal Treatment. Rats in sham and model groups
received 10mL/kg of distilled water per day by oral adminis-
tration. Rats in BBR treatment group received 120mg/kg/day
BBR dissolved in distilled water orally. All treatment lasted
for seven weeks.
2.5. Biochemical Analysis. At the end of the experiment,
animals were sacrificed by i.p. injection of 200mg/kg pen-
tobarbitone. Blood was collected and serum was separated
by centrifugation at 3000 g for 5min. Serum AST, ALT, and
TBil were quantified by a biochemical autoanalyzer. The
tissue hydroxyproline (HyP) level was examined with a HyP
detection kit (Jiancheng Bioengineering Institute, Nanjing,
China) following the manufacturer’s instructions.
2.6. Histological Analysis. Livers collected from different
groups of rats were rinsed with PBS and fixed in 4% buffered
formaldehyde for 24 h. Paraffin-embedded tissues were cut
into 5 𝜇m sections and stained with hematoxylin and eosin
(H&E). To evaluate chronic liver injury by a semiquantitative
scoring, five phases of liver injury were defined as follows: S0:
no observable scaring; S1: no extended portal area scaring; S2:
fibrotic portal area with intact lobule structure; S3: fibrosis
with broken lobule structure and no cirrhosis; and S4: cir-
rhosis. Fibrotic area within 1.5mm2 of each section was mea-
sured. Images were captured under light microscope (Leica
Microsystems Digital Imaging, Germany) with CCD camera
at the magnification of 10 × 10 (Leica DFC 280, Germany).
2.7. Cells and Cell Culture. The human hepatocyte cell line
L-02 and human HSC line hHS were obtained from Sun Yat-
Sen University (Guangdong, China). The cells were cultured
in Dulbecco’s Modified Eagle medium with high glucose
(4.5 g/L) with supplements of 10% Foetal Bovine Serum
(FBS) and 1% penicillin/streptomycin and incubated in a
humidified atmosphere containing 5% CO
2
at 37∘C.
2.8. Cell Viability Assay. Cell viability assay was performed
to examine the cytotoxicity of BBR to HSC cells. Briefly,
cells were cultured in 96-well cell culture plate in DMEM
supplemented with 10% FBS. Each well contained 10,000
cells for attachment overnight. A series of concentrations of
BBR were added to the cells to incubate. Then, 10 𝜇L of 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT, 5mg/mL, Sigma, USA) was added to each well 4 h
before the end of treatment and the incubationwas continued
at 37∘C. The medium was then discarded and 100 𝜇L DMSO
was added to dissolve the crystals with gentle pipetting. The
absorbancewas read at 575 nmon aMultiskanMSMicroplate
Reader (Labsystems, Finland).
2.9. Annexin V and Propidium Iodide (PI) Staining. Annexin
V and PI double stainingwas introduced to analyze cell apop-
tosis and necrosis. In brief, cells were trypsinized, collected,
and centrifuged. Cells were stained using the Annexin V
and PI double staining kit (Sigma-Aldrich, USA) in binding
buffer containing 100mMHEPES/NaOH, 1.4mMNaCl, and
25mM CaCl
2
, pH 7.5. Five 𝜇L 50 𝜇g/mL FITC-conjugated
Annexin V and 10 𝜇L 100 𝜇g/mL PI were added and samples
were incubated in dark at room temperature for 15min. The
cell suspension was then detected by flow cytometer (Epics
XL, Beckman Coulter, USA). Results were analyzed with the
FlowJo software (USA).
2.10. Transwell Migration Assay. hHSC motility upon BBR
treatment was examined in Millicell-PCF Cell Culture Insert
(24-well, 8.0 𝜇m,Millipore). Briefly, the inserts were standing
in 24-well cell culture plate. 5 × 104 cells in 100 𝜇L serum-
free medium were added to the insert, while 0.5mL 10%
FBS DMEM containing indicated concentrations of BBR was
added to each well of the 24-well plate. This was followed
by incubation in 5% CO
2
at 37∘C for 24 hr. The noninvading
cells on the upper surface were removed by cotton swabs.
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Figure 1: BBR attenuated hepatic fibrosis induced by BDL in rats.The common bile duct of rat was ligated with 3-0 silk and sectioned between
the ligatures. Rats in sham-operated control group had their bile duct exposed without ligation or section. Rats were randomised and received
either PBS or BBR (120mg/kg/day orally) for seven weeks. At the end of the study, rats were sacrificed and the serum and liver were collected.
(a) BBR reduced serumALT and AST in BDL rats. (b) BBR reduced the HyP content in the liver. (c) BBR reduced serum total bile acid (T.Bil)
in rats with BDL. (d) Histological analysis revealed that the fibrosis was inhibited by BBR treatment. ∗𝑝 < 0.05 and ∗∗𝑝 < 0.01 versus normal
group; #𝑝 < 0.05 and ##𝑝 < 0.01 versus the model group.
The cells that invaded across the transmembrane to the
lower surface of the membrane were fixed by ice cool 100%
ethanol and stained by 2% crystal violet (Sigma-Aldrich,
USA). Photographs of the stained migrated cells (3 random
fields per culture) were taken under an inverted microscope
at 400× and the mean number of cells of the 3 fields was
recorded.
2.11. JC-1 Staining. Themeasurement ofmitochondrialmem-
brane potential was conducted with JC-1 staining. Cells were
seeded in 35mm glass-bottom dishes and treated with BBR.
Cells were then stained with 10 𝜇g/mL JC-1 (Invitrogen,
USA) in dark for 30min and visualized under a fluorescence
microscope. Intense red fluorescence indicates the integrity
of mitochondrial membrane, while increased green fluores-
cence represents loss of mitochondrial membrane potential.
2.12. Immunofluorescence. Cells were seeded in 35mm glass-
bottomdishes and treated with BBR.The cells were then fixed
with 4% paraformaldehyde in PBS followed by incubation
with blocking buffer (5% normal goat serum and 0.03% Tri-
ton X-100 in PBS). Then, cells were incubated with antibody
against 𝛼-SMA at 4∘C overnight followed by wash. Alexa
Fluor-conjugated secondary antibody (Invitrogen, USA) was
added and cells were incubated in dark for 60min. Cell nuclei
were stained with 4󸀠,6-diamidino-2-phenylindole (DAPI).
The cells were observed under fluorescence microscope (Carl
Zeiss, USA) and images were captured with a CCD camera
(400×magnification).
2.13. Reverse-Transcription Quantitative Polymerase Chain
Reaction (RT-qPCR). Total RNA was extracted with total
RNApurification kit (Norgen, Canada). cDNAwas generated
with first-strand cDNA synthesis kit (Roche, USA) using
the collected RNA as template. The quantitative PCR was
conducted with SYBR Green I master mix (Roche, USA)
on LightCycler 480 (Roche, USA). The primer sequences of
target genes were listed in Table 1.
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Figure 2: BBR induced apoptosis in constitutively activated hHSC. (a) Constitutively activated hHSC in 96-well plate were treated with BBR
for 24 hr and cytotoxicity of BBR was determined by MTT assay. The IC
50
of BBR on hHSC was roughly 75 𝜇M. (b) hHSC were treated with
BBR for 12 hr or 24 hr. Apoptosis and necrosis were analyzed by Annexin V/PI dual staining and flow cytometry. (c) BBR-treated hHSC were
stained with JC-1 (10𝜇g/mL). Significant increase of green fluorescence with loss of red fluorescence indicated the relapse of mitochondrial
membrane integrity. (d) BBR regulated Bcl-2/Bax ratio in hHSC. The cells were treated with BBR for 24 hr and cell lysates were subjected to
Western blot hybridization. Increase of cleaved caspase-3 and caspase-9 and PARP indicated BBR induced apoptosis, while cyto C released
from mitochondria exhibited loss of membrane integrity. Upregulation of Bax with Bcl-2 inhibition was observed in BBR-treated cells.
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Figure 3: Nontoxic BBR suppressed the activity of hHSC. (a) The normal hepatocyte cell line L-02 in 96-well plates was treated with BBR
for 24 hr and cell viability was determined by MTT assay. The IC
50
of BBR on L-02 cells was around 250 𝜇M. (b) BBR suppressed hHSC
migration. Cells in serum-free medium were seeded onto the Transwell and medium containing 10% FBS was used as attractant to initiate
cell migration. After different doses of BBR were added, the cells were cultured for 24 hr, fixed with 4% paraformaldehyde, and then stained
with 2% crystal violet.Three images were captured for eachwell and the representative images are shown. BBR treatment significantly reduced
cell motility. (c) BBR downregulated 𝛼-SMA expression in constitutively activated hHSC. Cells were treated with BBR for 24 hr and then fixed
with 4% paraformaldehyde.The expression of 𝛼-SMAwas stained (red) and nuclei were stained withHoechst 33342 (blue).Three images were
captured per treatment group and the representative image of each group is shown. BBR treatment significantly reduced 𝛼-SMA expression
in constitutively activated hHSC. ∗∗𝑝 < 0.01 versus control.
2.14. Immunoblotting. Cells were lysed with the Radioim-
munoprecipitation Assay (RIPA) Buffer with the cOmplete
Cocktail Proteinase Inhibitor (Roche, USA) and phosphatase
inhibitor (1mM Na
3
VO
4
and 1mM NaF) on ice for 30min
followed by centrifugation at 14,000 rpm at 4∘C for 15min.
Supernatants were transferred and protein concentrations
were determined by BSA assay (Bio-Rad, USA). Equal yield
of protein was separated on SDS-PAGE and transferred onto
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Table 1: Primer sequence.
Forward Reverse
TGFB1 TGAACCGGCCTTTCCTGCTTCTCATG GCGGAAGTCAATGTACAGCTGCCGC
ACTA2 CCGACCGAATGCAGAAGGA ACAGAGTATTTGCGCTCCGAA
COL1A1 CAGCCGCTTCACCTACAGC TTTTGTATTCAATCACTGTCTTGCC
COL4A3 GCTGTCAACACCAGCTCTGA CGGTGCACCTGCTAATGTAA
ACTB CCAACCGCCAGAAGATGA CCAGAGGCGTACAGGGATAG
a polyvinylidene fluoride membrane (PVDF, Bio-Rad). The
membrane was then blocked in buffer containing 5% BSA,
Tris (10mmol/L, pH 7.4), NaCl (150mmol/L), and Tween
20 (1%) at room temperature for 1 hr with gentle shaking.
The membrane was then incubated with primary antibodies
at 4∘C overnight followed by incubation with appropriate
secondary antibody (Abcam, UK) at room temperature
for 1 hr. The immunoreactivities were detected using ECL
advanced kit (GE Healthcare, UK) and visualized using a
chemiluminescence imaging system (Bio-Rad, USA).
2.15. Statistical Analysis. Data were expressed as mean ±
standard deviation ofmeans (SD) and statistical comparisons
were conducted using one-way ANOVA. 𝑝 value lower than
0.05 was considered statistically significant.
3. Results
3.1. BBR Suppressed BDL-Induced Hepatic Fibrosis in Rats.
In the present study, hepatic fibrosis was induced by BDL
in rats to induce extrahepatic cholestasis. Significant serum
ALT and AST elevation was observed in BDL rats and
BBR treatment remarkably reduced serum ALT and AST
(Figure 1(a)). Content of HyP in the liver, as a biomarker of
hepatic fibrosis, wasmeasured, and BBR potently reduced the
liver content of HyP consistently (Figure 1(b)) and reduced
serum total bile acid level (Figure 1(c)). Histological analysis
revealed that administration of BBR attenuated the hepatic
fibrosis induced by BDL in rats (Figure 1(d)). Overall scores
of liver fibrosis in different groups are shown in Table 2.
3.2. Toxic Doses of BBR Induced Mitochondrial Apoptosis
of HSC through Altering Bcl-2/Bax Ratio and Subsequent
Caspase Activation. To explore possible mechanisms of the
antifibrotic effect of BBR, we focused on the HSC, which are
activated during fibrogenic process. hHSC, a constitutively
activated humanHSC line,was used to evaluate the cytotoxic-
ity of BBR. High dose of BBR exhibited toxic effects to hHSC
(IC
50
75 𝜇M, Figure 2(a)). Toxic dose of BBR could initiate
apoptosis of hHSC (Figure 2(b)). This effect may be due
to the increased permeability of mitochondrial membrane
in hHSC with exposure of toxic dose of BBR (Figure 2(c)),
which was indicated by the loss of mitochondrial membrane
integrity. Expression of Bcl-2 was significantly downregu-
lated upon BBR treatment, leading to Bcl-2/Bax imbalance
and mitochondrial membrane polarization (Figure 2(d)).
This observation was further confirmed by the release of
cytochrome C into cytoplasm, which initiated caspase acti-
vation subsequently (Figure 2(d)). These results suggest that
toxic dose of BBR may induce mitochondrial apoptosis in
hHSC.
3.3. Nontoxic Doses of BBR Suppress HSC Activation by
Inhibiting 𝛼-SMA Expression and Cell Migration. The toxic
dose of BBR on normal hepatic cell line L-02 was examined
to evaluate its possible adverse effect. It was shown that the
IC
50
value of BBR on L-02 cells was about 250 𝜇M, indicating
that high doses of BBR may exhibit some toxic action to
normal hepatocytes (Figure 3(a)). Further examining the
effect of BBR on HSC at nontoxic doses, we found that
BBR significantly downregulated the expression of 𝛼-SMA,
the biomarker of HSC activation, indicating that BBR might
inactivate the activated hHSC at nontoxic doses (Figure 3(b)).
Furthermore, BBR significantly downregulated hHSC motil-
ity (Figure 3(c)).
3.4. BBR Repressed 𝛼-SMA and Collagen mRNA Expres-
sion without Altering Smad2/3 Phosphorylation. The TGF-
𝛽/Smad signalling plays an important role in HSC activation
in liver fibrosis [21]. As BBR was reported to suppress TGF-
𝛽 expression in the plasma of patients with lung cancer
who were undergoing radiotherapy [22], the expression
of TGF-𝛽 was analyzed in our study to prove if similar
action of BBR could be found. However, in our study, we
observed no significant reduction of TGF-𝛽 expression in
BBR-treated hHSC (Figure 4(a)). Neither did BBR suppress
Smad2/3 phosphorylation (Figure 4(b)). However, BBR dose-
dependently inhibited the mRNA expression of 𝛼-SMA
(ACTA2), collagen 1A (COL1A1), and collagen IV (COL4A3)
(Figure 4(c)).
3.5. AMPK Activation Is Responsible for the Smad2/3 Inhi-
bition by BBR in HSC. Activation of AMPK signalling by
BBR was observed in hHSC (Figure 5(a)). Previous studies
have exhibited the role of AMPK activation in the treatment
against oxidative stress-induced liver injury [23] and it was
shown that AMPK activity is critical for the experimental
therapy of hepatic fibrosis as well [24]. In our study, fur-
ther examination was made to explore the role of AMPK
activation in BBR’s inhibitory effect of experimental hepatic
fibrosis. BBR suppression of 𝛼-SMA, COL1A1, and COL4A3
mRNA in hHSC was potently attenuated by the presence of
Compound C, an AMPK inhibitor (Figure 5(b)), suggesting
that BBR suppression of these mRNAs might be attributed
to AMPK activation in hHSC. A critical role for AMPK in
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Table 2: Histological analysis of the effect of BBR on BDL-induced liver fibrosis in rats.
Group Sample (𝑛) Fibrosis stage Fibrotic area within 1.5mm2
S0 S1 S2 S3 S4
Shammed 6 6 0 0 0 0 0.007 ± 0.005
Model 6 0 1 1 3 1 0.079 ± 0.025∗∗
BBR (120mg/kg) 6 0 3 2 1 0 0.032 ± 0.024∗,#
∗: 𝑝 < 0.05, ∗∗: 𝑝 < 0.01 versus shammed group; #: 𝑝 < 0.05 versus model group.
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Figure 4: BBR suppressed 𝛼-SMA, without affecting Smad2/3 phosphorylation. (a) BBR did not affect the TGF-𝛽 production in hHSC. The
expression of TGF-𝛽 mRNA transcript was analyzed with RT-qPCR. No significant difference between treatment and nontreatment group
was observed. (b) BBR did not inhibit Smad2/3 phosphorylation in hHSC. Immunoblotting analysis using specific antibodies revealed no
significant difference between treatment and nontreatment group in the phosphorylation of Smad2/3. (c) BBR suppressed the expression
of profibrogenic factors. The downstream targets of Smad2/3, fibrogenic 𝛼-Sma, Col1a1, and Col4a3 were analyzed by RT-qPCR. Significant
reduction of 𝛼-SMA, Col1A1, and Col4a3 mRNAs was observed in BBR-treated cells in a dose-dependent manner. ∗∗𝑝 < 0.01 versus control.
BBR repression of hHSC activation was further confirmed by
the fact that BBR repression of 𝛼-SMA expression and hHSC
motility were both prevented by Compound C (Figures 5(c)
and 5(d)).
4. Discussion
Critical role of HSC activation in the early development of
liver fibrosis has been revealed by previous studies [25]. The
activation of HSC initiates its proliferation as well as the
production of extracellular matrix (ECM) proteins such as 𝛼-
SMA and collagens [6]. Attempts have been made to explore
the use of BBR in the therapy for fibrosis-related hepatic
diseases. Previous studies have shown that BBR could be
used for the treatment against hypertyraminemia in patients
with liver cirrhosis [26], which was correlated with BBR’s
capacity of reducing blood lipid in hyperlipidemic patients
[27]. Experimental studies have been also conducted, the
results of which exhibit the potential of BBR in ameliorating
hepatic fibrosis with various mechanisms [28, 29]. In par-
ticular, it was shown that the antioxidative activity of BBR
contributes to improvement of experimental hepatic fibrosis
via stimulating matrix metalloproteinase-2 (MMP-2) [30].
Our findings further showed that apoptosis of HSC could
be initiated by toxic doses of BBR, and Bcl-2/Bax-mediated
mitochondrial membrane potential loss may be involved in
induction of HSC apoptosis by BBR. Interestingly, we found
that nontoxic doses of BBR downregulated the activation of
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Figure 5: Activation of AMPK was responsible for BBR inhibition of HSC activation. (a) BBR dose-dependently activated AMPK signalling
in HSC. (b) Suppression of AMPK with Compound C attenuated inhibition of 𝛼-SMA, Col1A1, and Col4a3 transcripts by BBR. Cells were
treated with BBR alone or in combination with AMPK inhibitor Compound C (25 𝜇M) for 24 hr and then RNA was collected. Expression of
𝛼-SMA, Col1A1, and Col4a3 mRNA transcripts was analyzed with RT-qPCR. Significant restoration of 𝛼-SMA, Col1A1, and Col4a3 mRNA
expression was found when BBR was given in combination with Compound C. (c) Inhibition of AMPK reactivated BBR-treated hHSC.
Significant reduction of 𝛼-SMA distribution was observed in BBR-treated cells, while recovery of 𝛼-SMA was found when BBR was given
in combination with AMPK inhibitor Compound C (25𝜇M). (d) hHSC motility was recovered, when cells were treated with BBR in the
presence of Compound C (25 𝜇M). ∗∗𝑝 < 0.01 versus control. Δ𝑝 < 0.05 versus the same treatment in the absence of Compound C.
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Figure 6: Proposed mechanisms of BBR regulation of HSC.
HSC, suppressing production of ECM proteins, preventing
deregulation of hepatic architecture and protecting hepato-
cytes from hepatocellular dysfunction (Figure 6) [31].
It has been previously shown that the activity of AMPK
signalling is a critical factor in the prevention of hepatic
fibrogenesis. In AMPK-deficient mice, the fibrogenesis and
liver fibrosis could be enhanced dramatically, and initiation
of AMPK could suppress HSC proliferation and collagen
expression [31]. The preventive effect of AMPK on hepatic
fibrosis was further evidenced by the fact that an adipocy-
tokine adiponectin could disrupt leptin-mediated hepatic
fibrosis through the activation of AMPK in HSC [24].
A recent study showed that berberine can replenish the
activity of AMPK in the liver of carbon tetrachloride- (CCl
4
)
treated mice [32]; however, whether activation of AMPK by
berberine is responsible for the improvement of experimental
fibrosis remains not clear. Furthermore, whether activation
of AMPK by berberine can suppress activated hepatic stellate
cells, which majorly mediates fibrogenesis in the liver, was
not studied. In our study, we observed that hepatic fibrosis
induced by BDL could be attenuated by BBR, which in hHSC
activates AMPK signalling and inhibits hHSC migration and
𝛼-SMA production. Inhibition of AMPK by Compound C
potently reduced the inhibitory effect on hHSC activation,
which was evidenced by the fact that cell motility and 𝛼-
SMA expression were restored in BBR-treated cells in the
presence of Compound C. These findings support a central
role of AMPK activation in BBR’s effect on HSC activation
and subsequent fibrogenesis.
We noticed that BBR has no effect on the signal
transduction of TGF-𝛽/Smad. BBR neither suppresses
the TGF-𝛽 expression in HSC nor inhibits Smad2/3
phosphorylation. However, the expression of profibrogenic
factors 𝛼-SMA, COL1A1, and COL4A3 was inhibited by
BBR and this effect could be attenuated by inhibition of
AMPK by Compound C. These observations indicate that
activation of AMPK could repress fibrogenesis without
affecting Smad2/3 phosphorylation. A previous study
showed that transcription activity mediated by Smad2/3
requires cooperation of transcription coactivators CBP and
p300, which initiate the N-terminal acetylation of Smad2/3
[33, 34]. Phosphorylated AMPK was reported to bind with
p300, initiate its proteasomal degradation, and consequently
inhibit Smad2/3 transcription activity without affecting their
phosphorylation [35]. Deletion of p300 has been found to
suppress fibrogenic collagen type I and 𝛼-SMA expression
and lead to fibrogenesis inhibition [35, 36]. Our findings
on the critical role for BBR activation of AMPK in HSC
shed light on the antifibrotic action of BBR and support its
potential value for the treatment of fibrosis in liver disease.
5. Conclusion
BBR is a promising agent for treating liver fibrosis through
multiple mechanisms, at least partially by directly targeting
HSC and by inhibiting the AMPK pathway. Its value as
an antifibrotic drug in patients with liver disease deserves
further investigation.
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